Sam Altman has a knack for finding the stories that make AI feel less like a science experiment and more like a miracle. This week, in a long conversation with journalist Laurie Segall, the OpenAI CEO dropped one that genuinely stopped me cold.

"The coolest meeting I had this week was a guy who was not an expert that used ChatGPT to make a custom mRNA vaccine for his dogs cancer," Altman said.

The guy is Paul Conyngham, an Australian tech CEO with zero medical training. His dog Rosie had been misdiagnosed. By the time anyone caught the cancer, it was too late for traditional treatment. Most people would have accepted the prognosis. Conyngham opened ChatGPT instead.

What followed was not some sci-fi montage. It was a man having hundreds of conversations with AI models, including ChatGPT, Gemini, and Grok, asking increasingly specific questions about cancer therapies. The AI recommended sequencing Rosies genome and analyzing her DNA to identify mutated genes. He used Googles AlphaFold protein structure model to map the mutations. ChatGPT then pointed him toward researchers at the University of New South Wales who could actually synthesize a custom mRNA vaccine based on that data.

They built the vaccine. They administered it. And according to Phys.org, it appears to have worked.

Why This Actually Matters

Let me be clear about what happened here. Conyngham did not create a vaccine. He is not a scientist. What he did was use AI as a research accelerator that connected him to the right knowledge, the right techniques, and the right people faster than any human could have navigated alone. The actual vaccine was developed by real researchers using real science. But without ChatGPT acting as the connective tissue, that collaboration never happens.

This is the use case that AI companies have been promising for years: not replacing doctors, but giving regular people the ability to navigate complex medical research at the speed of an expert. The fact that it worked on a dog does not make it less significant. Personalized mRNA vaccines for cancer are one of the most promising frontiers in human medicine. If a tech CEO with no background can orchestrate one for his pet, the barrier to entry for human applications just got a lot lower.

Conyngham is now opening his research to other dog owners through a public Google Form on LinkedIn. He flew to San Francisco to meet Altman in person. The coolest meeting of the week, indeed.

The Billion Dollar Solo Act

Altman also casually mentioned that someone has already used OpenAI tools to build a billion-dollar company as a solo founder. He would not name the person or the company. But if true, that is the most important data point in the entire AI economy debate. Not because it proves AI replaces teams. Because it proves AI lets one person with the right vision skip the team entirely.

The dog vaccine story is heartwarming. The billion-dollar solo company story is terrifying for anyone who thinks their job is safe because they work on a team. Both stories point in the same direction: the gap between what one person can do with AI and what they could do without it is getting wider every week.

First reported by TechRadar, based on the Mostly Human podcast with Laurie Segall. Rosies story originally reported by Phys.org.